Pipeline

MeMed started by tackling the FEVER ENCOUNTER the most prevalent medical indication

The Fever Encounter presents 3 major clinical dilemmas.  MeMed is striving to resolve the 3 clinical dilemmas presented by the fever encounter.

MeMed™ Alert

Our signature’s host biomarkers have been shown to potentially predict disease severity when integrated into a proprietary severity score algorithm.¹ Early detection of patients that are more likely to deteriorate is of significant value. It may aid in patient management by, on the one hand, identifying patients requiring more extensive medical intervention (such as hospitalization or ICU admission) and, on the other hand, patients that may be discharged. Also, it may potentially reveal the opportunity for early treatment, which can lead to improved patient outcomes. The test may contribute to a more efficient use of medical resources, especially during an epidemic outbreak

¹Oved K, Cohen A, Boico O, et al. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Protein as a Marker for Disease Severity in Patients With Acute Infection. Open Forum Infectious Diseases 2016, Volume 3, Issue suppl 1, 236

early.jpg

MeMed Early™

Infected individuals are often contagious prior to onset of clinical symptoms, and sometimes even in their absence. Currently, these contagious, yet asymptomatic, individuals are unidentifiable in real-time and can only be detected if symptoms manifest after they have already potentially infected others. Identification of pre-symptomatic and asymptomatic carriers may aid in reducing the spread of infection. This is of critical importance during times of an epidemic, allowing for regular screening and monitoring of health care workers and other high exposure risk individuals. A pre-symptomatic tool may be especially useful in a limited-resource healthcare setting to avoid unnecessary isolation and reduce in-hospital infections. 

Depositphotos_63169557_l-2015.jpg

RNA Immune Response

Over the past years, MeMed and collaborators have performed extensive measurements of the human transcriptome in various disease states using state-of-the-art high throughput technologies, and identified novel RNA-based biomarkers including mRNAs, non-coding RNAs and small RNAs. A novel line of proprietary products that rely on the RNA immune response to infectious diseases and inflammatory disorders. This line of RNA based tests is suitable for the central lab but not the point-of-need.